Cure Today

FDA Fast Tracks ITM-94 For Clear Cell Renal Cell Carcinoma Diagnosis

ITM-94, a gallium-68-radiolabeled PET imaging agent, targets carbonic anhydrase IX, crucial in tumor growth and metastasis. The FDA's fast track designation aims to expedite ITM-94's development for ...
Business Insider

ITM Receives U.S. FDA Fast Track Designation for ITM-94 as a Diagnostic Agent for Clear Cell Renal Cell Carcinoma

ITM-94 forms a theranostic pair with therapeutic candidate ITM-91, targeting carbonic anhydrase IX (CAIX) in clear cell renal cell carcinoma Garching / Munich, Germany, November 17, 2025 – ITM Isotope ...
Morningstar

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)

Garching / Munich, Germany, and Lausanne, Switzerland - June 23, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm, a Swiss-based, global ...
Mena FN

ITM Receives U.S. FDA Fast Track Designation For ITM-94 As A Diagnostic Agent For Clear Cell Renal Cell Carcinoma

ITM-94 forms a theranostic pair with therapeutic candidate ITM-91, targeting carbonic anhydrase IX (CAIX) in clear cell renal cell carcinoma “The FDA's Fast Track designation is a validation of ITM-94 ...